Alnylam Pharmaceuticals, Inc. (ALNY)

Alnylam Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	2,462	2,248	1,828	1,037	844.29	492.85
Revenue Growth (YoY)	5.01%	22.97%	76.23%	22.88%	71.31%	124.28%
Cost of Revenue	402.72	323.37	310.41	168.82	140.14	78.05
Gross Profit	2,059	1,925	1,518	868.6	704.14	414.8
Selling, General & Admin	1,080	975.53	795.65	770.66	620.64	588.42
Research & Development	1,160	1,126	1,004	883.02	792.16	654.82
Operating Expenses	2,239	2,102	1,800	1,654	1,413	1,243
Operating Income	-180.19	-176.89	-282.18	-785.07	-708.65	-828.44
Interest Expense	-152.24	-141.86	-121.22	-155.97	-143.02	-84.5
Interest & Investment Income	119.32	121.99	95.56	24.81	1.58	11.81
Other Non Operating Income (Expenses)	-162.44	-177.6	-108.74	-100.86	-57.75	-8.52
EBT Excluding Unusual Items	-375.54	-374.35	-416.57	-1,017	-907.84	-909.64
Gain (Loss) on Sale of Investments	-4.04	-3.02	-16.94	-33.31	55.7	54.04
Other Unusual Items	-	-	-	-76.59	-	-
Pretax Income	-379.58	-377.38	-433.52	-1,127	-852.14	-855.6
Income Tax Expense	-60.49	-99.22	6.73	4.16	0.68	2.68
Net Income	-319.09	-278.16	-440.24	-1,131	-852.82	-858.28
Net Income to Common	-319.09	-278.16	-440.24	-1,131	-852.82	-858.28
Shares Outstanding (Basic)	130	128	125	122	118	115
Shares Outstanding (Diluted)	130	128	125	122	118	115
Shares Change (YoY)	2.84%	2.20%	2.64%	2.73%	3.01%	5.24%
EPS (Basic)	-2.46	-2.18	-3.52	-9.30	-7.20	-7.46
EPS (Diluted)	-2.46	-2.18	-3.52	-9.30	-7.20	-7.46
Free Cash Flow	-52.09	-42.59	41.95	-613.33	-718.07	-685.32
Free Cash Flow Per Share	-0.40	-0.33	0.34	-5.04	-6.06	-5.96
Gross Margin	83.64%	85.62%	83.02%	83.73%	83.40%	84.16%
Operating Margin	-7.32%	-7.87%	-15.43%	-75.68%	-83.94%	-168.09%
Profit Margin	-12.96%	-12.37%	-24.08%	-109.04%	-101.01%	-174.14%
Free Cash Flow Margin	-2.12%	-1.89%	2.29%	-59.12%	-85.05%	-139.05%
EBITDA	-123.69	-120.22	-228.12	-740.6	-661.09	-793.67
EBITDA Margin	-5.02%	-5.35%	-12.48%	-71.39%	-78.30%	-161.03%
D&A For EBITDA	56.5	56.67	54.05	44.47	47.57	34.77
EBIT	-180.19	-176.89	-282.18	-785.07	-708.65	-828.44
EBIT Margin	-7.32%	-7.87%	-15.43%	-75.67%	-83.94%	-168.09%
Revenue as Reported	2,462	2,248	1,828	1,037	844.29	492.85
Advertising Expenses	-	29.7	12.4	11.7	-	-

Updated Jul 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q